Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.45 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 5/20 | 0.40 |
| ▸ | NOS1 | P29475 | 4/20 | 0.40 |
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24788157 | 0.90 | OTC (0.47) | GLP1ROTCNOS2NOS1NOS3 | |
| SCHEMBL24470266 | 0.90 | GLP1R (0.48) | GLP1ROTCNOS1NOD1MEN1 | |
| SCHEMBL13640939 | 0.90 | GLP1R (0.41) | GLP1RFOLH1MEN1KMT2A | |
| SCHEMBL24788148 | 0.90 | GLP1R (0.50) | GLP1ROTCNOS2NOS1NOS3 | |
| SCHEMBL24788082 | 0.90 | GLP1R (0.45) | GLP1ROTCNOS2NOS1NOS3 | |
| SCHEMBL22844085 | 0.88 | GSR (0.45) | GLP1ROTCNOD1 | |
| SCHEMBL19135682 | 0.88 | GLP1R (0.51) | GLP1ROTCCYP1A2NOD1 | |
| SCHEMBL19803897 | 0.88 | OTC (0.45) | GLP1ROTCNOS2NOS1NOS3 | |
| SCHEMBL1953200 | 0.87 | OTC (0.49) | GLP1ROTCNOS2NOS1NOS3 | |
| SCHEMBL30409031 | 0.87 | OTC (0.49) | GLP1ROTCNOS2NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | MERCK SHARP & DOHME LLC (US) | 2022-12-20 | — | — | US | disclosed |
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | UCB HOLDINGS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180021402-A1 | MODULATORS OF COMPLEMENT ACTIVITY | C3AR1, C1QBP, C5AR1 | GLP1R 575/4885OTC 2219/4885NOS2 4015/4885 |
| US-11530244-B2 | Cyclic polypeptides for PCSK9 inhibition | PCSK9, LDLR, PCSK7 | GLP1R 13/4885OTC 3433/4885NOS2 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.